Investor Information
|
Jefferies 2013 Global Healthcare Conference Jun 5, 2013 at 11:30 AM ET Goldman Sachs 34th Annual Global Healthcare Conference Jun 13, 2013 at 9:20 AM PT 4Q and FY2013 Results and FY2014 Guidance release Aug 2, 2013 at 6:30 AM ET 4Q and FY2013 Results and FY2014 Guidance call Aug 2, 2013 at 8:00 AM ET |
|
||||||||||||
Corporate Profile
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s TAP technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's highly potent cancer cell-killing agents specifically to tumor cells. Ten TAP compounds are now in the clinic, of which three are wholly owned by the Company. The most advanced compound using ImmunoGen's TAP technology, Kadcyla™, has been approved for marketing in the US and Switzerland, and is undergoing regulatory review in the European Union and Japan. Kadcyla is being commercialized in the US by Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.
Shareholder Inquiries
Inquiries related to the Company may be directed to the Investor Relations department at our headquarters. Communications related to stock and transfer requirements, including lost stock certificates and change of name or address, should be directed to the Transfer Agent.
Corporate Headquarters
ImmunoGen, Inc. |
Transfer Agent and Registrar
Broadridge Corporate Issuer Solutions, Inc. |
Corporate Counsel
Mintz, Levin, Cohn, Ferris, |
Independent Accountants
Ernst & Young LLP |
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever ImmunoGen, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Quotes delayed at least 20 minutes. Market data provided by eSignal.
